Weslie Janeway joins the board of directors at cell coding company bit.bio

Cell coding company bit.bio has expanded its board of directors with the appointment of distinguished investor, philanthropist, and scientist Weslie Janeway, a Cambridge resident since 2006.

Weslie, an early investor in bit.bio, brings a wealth of board and stem cell research expertise to bit.bio, a finalist in the upcoming 2023 Science &Technology awards.

Mark Kotter, bit.bio CEO and founder, said: “We are thrilled to welcome Weslie Janeway to our board of directors. Her expertise in financial services, genetics, and her passion for innovation make her a perfect fit for our company.

“We are confident that her leadership and guidance will contribute significantly to our mission of coding cells for novel cures. As a founding investor of bit.bio, Weslie will also serve on the audit and compensation committees.”

Weslie Janeway said: “[The Cambridge life sciences sector] is thriving thanks to amazing scientists with entrepreneurial vision. More private and public funding is needed. Too many important projects never make it to completion because the money runs out.”

She added: “When I first met Mark, the founder and CEO through my studies at Cambridge, I immediately saw the potential of his scientific discovery - the investor in me thought “there’s a company here” which is why I invested. I’m now looking forward to supporting the company as a board member using my scientific background as well.

“I’m convinced that the technology will transform drug development by enabling highly consistent and scalable cell standards which can be expanded to run clinical trials in a dish. The consistency and scale of bit.bio’s products can also address the reproducibility crisis, which casts a shadow on the industry.”